Immutep Ltd ADR (IMMP)

$1.65 +0.03 (1.85%)
Market Cap 242.20M
Revenue (ttm) 0.00
Net Income (ttm) -39.78M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.01
Volume 182,800
Avg Vol 76,956
Day's Range N/A - N/A
Shares Out 146.79M
Stochastic %K 38%
Beta 1.71
Analysts Strong Sell
Price Target $9.50

Company Profile

Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers. The company's product pipeline also includes TACTI-004, which is in phase III clinical trial for the treatment of first line non-small cell lung...

Industry: Biotechnology
Sector: Healthcare
Phone: 61 2 8315 7003
Fax: 61 2 8569 1880
Address:
Australia Square, Level 32 264 George Street, Sydney, Australia
DARKP00L
DARKP00L Sep. 8 at 12:17 PM
$IMMP 08:13 on Sep. 08 2025 Immutep Limited Announces That An Abstract From Its EFTISARC-NEO Phase 2 Trial Has Been Accepted For Oral Presentation At The CTOS 2025 Annual Meeting In November. The Study Is The First To Evaluate Eftilagimod Alpha In A Neoadjuvant Setting, Combined With Radiotherapy And Keytruda, For Patients With Soft Tissue Sarcoma #tradeideas
0 · Reply
DARKP00L
DARKP00L Sep. 8 at 12:17 PM
$IMMP 08:12 on Sep. 08 2025 Immutep To Present Phase II EFTISARC-NEO Trial Data On Efti + KEYTRUDA Combo In Soft Tissue Sarcoma At CTOS 2025 #tradeideas
0 · Reply
DARKP00L
DARKP00L Sep. 8 at 12:16 PM
$IMMP 08:07 on Sep. 08 2025 Immutep Limited Announces That An Abstract From Its EFTISARC-NEO Phase 2 Trial Has Been Accepted For Oral Presentation At The CTOS 2025 Annual Meeting In November. The Study Is The First To Evaluate Eftilagimod Alpha In A Neoadjuvant Setting, Combined With Radiotherapy And Keytruda, For Patients With Soft Tissue Sarcoma #tradeideas
0 · Reply
theinvestaar
theinvestaar Sep. 8 at 2:36 AM
$IMMP News out!!! yeah baby another oral presentation for November in soft tissue sarcoma. Things are heating up now.
0 · Reply
BigTimePennyStocks
BigTimePennyStocks Sep. 7 at 8:59 PM
Small-Caps with Catalysts this week: 👇👇 ( $GNPX, $AEMD, $NXL, $IMMP, $COCP, etc...) #NASDAQ #NYSE
0 · Reply
NOCKNOCK
NOCKNOCK Sep. 5 at 7:37 PM
$IMMP 👇one thing for certain, I'll be here to find out.
0 · Reply
bylocehi
bylocehi Sep. 5 at 6:37 PM
$IMMP The new investigator initiated breast cancer trial at George Washington seeks to determine pathological complete response (pCR) after neoadjuvant chemotherapy (NAC) and Efti treatment Their protocol seems different than other studies. Do these guy think the can cure cancer by priming APCs with eftilagimod first then use current therapies to provide APCs with cancer antigens to optimize cellular immune response? This could be the big breakthrough we need.
0 · Reply
hendo7179
hendo7179 Sep. 5 at 5:10 AM
$IMMP absolute trash, year after year talks of a buyout, and here we are close to the end of 2025 and looking down the barrel of another CR.
0 · Reply
theinvestaar
theinvestaar Sep. 5 at 4:16 AM
$IMMP Sooooon
0 · Reply
Jagr99
Jagr99 Sep. 5 at 12:33 AM
$IMMP trash
0 · Reply
Latest News on IMMP
Immutep Quarterly Activities Report Q4 FY25

Jul 30, 2025, 8:00 AM EDT - 5 weeks ago

Immutep Quarterly Activities Report Q4 FY25

Immutep to Present Pivotal TACTI-004 Trial in Progress Poster at the 2025 World Conference on Lung Cancer

Jul 29, 2025, 8:00 AM EDT - 5 weeks ago

Immutep to Present Pivotal TACTI-004 Trial in Progress Poster at the 2025 World Conference on Lung Cancer

Immutep's Efti with Radiotherapy & KEYTRUDA® (pembrolizumab) Meets Primary Endpoint in Phase II for Soft Tissue Sarcoma

May 27, 2025, 8:00 AM EDT - 3 months ago

Immutep's Efti with Radiotherapy & KEYTRUDA® (pembrolizumab) Meets Primary Endpoint in Phase II for Soft Tissue Sarcoma

Immutep Reports 61% Response Rate In Lung Cancer Trial With Keytruda-Based Triple Combo

May 15, 2025, 3:50 PM EDT - 4 months ago

Immutep Reports 61% Response Rate In Lung Cancer Trial With Keytruda-Based Triple Combo

Immutep Limited: Surging On Positive Head And Neck Data

May 8, 2025, 8:46 AM EDT - 4 months ago

Immutep Limited: Surging On Positive Head And Neck Data

Immutep to Participate in Upcoming Investor Conferences

Apr 2, 2025, 8:00 AM EDT - 5 months ago

Immutep to Participate in Upcoming Investor Conferences

Immutep Quarterly Activities Report Q2 FY25

Jan 31, 2025, 8:00 AM EST - 7 months ago

Immutep Quarterly Activities Report Q2 FY25

Immutep Limited: Continuing To Make The Case For Eftilagimod

Jan 28, 2025, 4:37 PM EST - 7 months ago

Immutep Limited: Continuing To Make The Case For Eftilagimod

Immutep Announces Initial Safety Data from First-in-Human Phase I Trial Evaluating IMP761

Dec 17, 2024, 8:00 AM EST - 9 months ago

Immutep Announces Initial Safety Data from First-in-Human Phase I Trial Evaluating IMP761

Immutep Reports Promising New Data in Head and Neck Cancer at ESMO Immuno-Oncology 2024

Dec 12, 2024, 8:15 AM EST - 9 months ago

Immutep Reports Promising New Data in Head and Neck Cancer at ESMO Immuno-Oncology 2024

Immutep: Potential Of Efti As New Standard Of Care For NSCLC Patients

Nov 15, 2024, 3:18 PM EST - 10 months ago

Immutep: Potential Of Efti As New Standard Of Care For NSCLC Patients

Immutep's Lead Cancer Drug Shows Promising 2-Year Survival Data In Lung Cancer Trial

Nov 14, 2024, 11:16 AM EST - 10 months ago

Immutep's Lead Cancer Drug Shows Promising 2-Year Survival Data In Lung Cancer Trial

Immutep's Efti Shows Excellent Survival Data from INSIGHT-003 Trial in Non-Small Cell Lung Cancer

Nov 14, 2024, 8:15 AM EST - 10 months ago

Immutep's Efti Shows Excellent Survival Data from INSIGHT-003 Trial in Non-Small Cell Lung Cancer

Immutep Quarterly Activities Report Q1 FY25

Oct 29, 2024, 8:00 AM EDT - 11 months ago

Immutep Quarterly Activities Report Q1 FY25

Immutep to Participate in the 2024 Maxim Healthcare Virtual Summit

Oct 10, 2024, 8:00 AM EDT - 11 months ago

Immutep to Participate in the 2024 Maxim Healthcare Virtual Summit

Immutep: Navigating The Bumps In The Road

Oct 7, 2024, 9:10 AM EDT - 11 months ago

Immutep: Navigating The Bumps In The Road

Immutep's Efti in Combination with MSD's KEYTRUDA® Leads to Positive Efficacy with Favourable Safety in First Line Head and Neck Cancer

Sep 16, 2024, 8:00 AM EDT - 1 year ago

Immutep's Efti in Combination with MSD's KEYTRUDA® Leads to Positive Efficacy with Favourable Safety in First Line Head and Neck Cancer

Immutep Quarterly Activities Report Q4 FY24

Jul 31, 2024, 8:00 AM EDT - 1 year ago

Immutep Quarterly Activities Report Q4 FY24

Immutep: Positive Efti Treatment Data Leads To Late-Stage Programs

Jul 15, 2024, 1:54 PM EDT - 1 year ago

Immutep: Positive Efti Treatment Data Leads To Late-Stage Programs

Immutep Reports Positive Results in First Line Head and Neck Squamous Cell Carcinoma Patients with Negative PD-L1 Expression

Jul 11, 2024, 6:40 PM EDT - 1 year ago

Immutep Reports Positive Results in First Line Head and Neck Squamous Cell Carcinoma Patients with Negative PD-L1 Expression

Immutep Announces Details for Oral Presentation at ESMO Virtual Plenary Session and Webcast to Discuss Clinical Results

Jul 3, 2024, 8:00 AM EDT - 1 year ago

Immutep Announces Details for Oral Presentation at ESMO Virtual Plenary Session and Webcast to Discuss Clinical Results

Immutep Signs Exclusive License Agreement with Cardiff University for Next Generation Anti-LAG-3 Molecules for Cancer

Jun 25, 2024, 8:00 AM EDT - 1 year ago

Immutep Signs Exclusive License Agreement with Cardiff University for Next Generation Anti-LAG-3 Molecules for Cancer

Immutep successfully completes institutional placement and institutional component of entitlement offer

Jun 5, 2024, 6:00 AM EDT - 1 year ago

Immutep successfully completes institutional placement and institutional component of entitlement offer

Immutep Announces Clinical Collaboration with MSD to Evaluate Efti in Combination with KEYTRUDA® (pembrolizumab) in Pivotal Phase III Trial

Jun 2, 2024, 8:38 PM EDT - 1 year ago

Immutep Announces Clinical Collaboration with MSD to Evaluate Efti in Combination with KEYTRUDA® (pembrolizumab) in Pivotal Phase III Trial

Immutep Presents Data from Safety Lead-in Phase of AIPAC-003 at ESMO Breast 2024

May 15, 2024, 8:00 AM EDT - 1 year ago

Immutep Presents Data from Safety Lead-in Phase of AIPAC-003 at ESMO Breast 2024

Positive Initial Clinical Data Reported from Immutep's Efti Combined with Radiotherapy and Checkpoint Inhibitor from Phase II Trial in Soft Tissue Sarcoma

May 2, 2024, 8:00 AM EDT - 1 year ago

Positive Initial Clinical Data Reported from Immutep's Efti Combined with Radiotherapy and Checkpoint Inhibitor from Phase II Trial in Soft Tissue Sarcoma

Immutep: Realizing The Expected Catalysts, With More To Come

May 1, 2024, 12:39 PM EDT - 1 year ago

Immutep: Realizing The Expected Catalysts, With More To Come

Immutep Quarterly Activities Report Q3 FY24

Apr 29, 2024, 8:00 AM EDT - 1 year ago

Immutep Quarterly Activities Report Q3 FY24

Immutep Announces Positive Preliminary Topline Results from TACTI-003 Cohort B

Apr 24, 2024, 8:00 AM EDT - 1 year ago

Immutep Announces Positive Preliminary Topline Results from TACTI-003 Cohort B

Immutep Appoints Leading Research Institute to Conduct First-in-Human Phase I Study of IMP761

Apr 18, 2024, 8:00 AM EDT - 1 year ago

Immutep Appoints Leading Research Institute to Conduct First-in-Human Phase I Study of IMP761

Immutep Receives Positive Feedback from the Spanish Medicines Agency for Upcoming TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer

Apr 17, 2024, 8:00 AM EDT - 1 year ago

Immutep Receives Positive Feedback from the Spanish Medicines Agency for Upcoming TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer

Immutep Announces First Clinical Data from 90mg Dosing of Efti

Mar 5, 2024, 8:00 AM EST - 1 year ago

Immutep Announces First Clinical Data from 90mg Dosing of Efti

Immutep Quarterly Activities Report Q2 FY24

Jan 30, 2024, 8:00 AM EST - 1 year ago

Immutep Quarterly Activities Report Q2 FY24

First Patient Dosed in Trial Evaluating Efti and the Anti-PD-L1 Therapy BAVENCIO® in Metastatic Urothelial Cancer

Jan 4, 2024, 8:00 AM EST - 1 year ago

First Patient Dosed in Trial Evaluating Efti and the Anti-PD-L1 Therapy BAVENCIO® in Metastatic Urothelial Cancer

Immutep: Upcoming Signals For 2024 (Maintain Buy)

Jan 3, 2024, 5:04 PM EST - 1 year ago

Immutep: Upcoming Signals For 2024 (Maintain Buy)

Immutep Receives Constructive Regulatory Feedback on TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer

Dec 21, 2023, 8:00 AM EST - 1 year ago

Immutep Receives Constructive Regulatory Feedback on TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer

Immutep Receives A$2.6 million R&D Tax Incentive from French Government

Dec 7, 2023, 8:00 AM EST - 1 year ago

Immutep Receives A$2.6 million R&D Tax Incentive from French Government

Immutep Announces Site Expansion for INSIGHT-003 Phase I Trial

Nov 22, 2023, 8:00 AM EST - 1 year ago

Immutep Announces Site Expansion for INSIGHT-003 Phase I Trial

Immutep Completes Enrollment in TACTI-003 Phase IIb Trial of Efti and KEYTRUDA® in First Line Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma

Nov 9, 2023, 8:00 AM EST - 1 year ago

Immutep Completes Enrollment in TACTI-003 Phase IIb Trial of Efti and KEYTRUDA® in First Line Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma

Immutep Announces Completion of the Safety Lead-In and Opening of the Randomized Phase II of the AIPAC-003 Phase II/III Trial in Metastatic Breast Cancer

Nov 6, 2023, 8:00 AM EST - 1 year ago

Immutep Announces Completion of the Safety Lead-In and Opening of the Randomized Phase II of the AIPAC-003 Phase II/III Trial in Metastatic Breast Cancer

Immutep Announces New Biomarker Data from TACTI-002 Phase II in First Line Non-Small Cell Lung Cancer

Nov 3, 2023, 12:00 PM EDT - 2 years ago

Immutep Announces New Biomarker Data from TACTI-002 Phase II in First Line Non-Small Cell Lung Cancer

Immutep to Participate in November Investor Events

Nov 2, 2023, 8:00 AM EDT - 2 years ago

Immutep to Participate in November Investor Events

Immutep Quarterly Activities Report Q1 FY24

Oct 31, 2023, 8:00 AM EDT - 2 years ago

Immutep Quarterly Activities Report Q1 FY24

Immutep receives ~A$1.13 million R&D Tax Incentive

Oct 25, 2023, 8:00 AM EDT - 2 years ago

Immutep receives ~A$1.13 million R&D Tax Incentive

Immutep Reports Promising Clinical Data from INSIGHT-003 Trial at ESMO Congress 2023

Oct 24, 2023, 8:00 AM EDT - 2 years ago

Immutep Reports Promising Clinical Data from INSIGHT-003 Trial at ESMO Congress 2023

Immutep's Efti in Combination with KEYTRUDA® Generates Excellent Overall Survival Benefit in Patients with Metastatic Non-Small Cell Lung Cancer

Oct 23, 2023, 8:00 AM EDT - 2 years ago

Immutep's Efti in Combination with KEYTRUDA® Generates Excellent Overall Survival Benefit in Patients with Metastatic Non-Small Cell Lung Cancer

Immutep Announces Publication of Abstracts at ESMO Congress 2023

Oct 16, 2023, 8:00 AM EDT - 2 years ago

Immutep Announces Publication of Abstracts at ESMO Congress 2023

Immutep Announces Abstract Accepted for Presentation at the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting

Oct 3, 2023, 8:00 AM EDT - 2 years ago

Immutep Announces Abstract Accepted for Presentation at the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting

Commercial Manufacturing of Eftilagimod Alpha at 2000L Scale Granted Authorization for Clinical Trial Use

Sep 21, 2023, 8:00 AM EDT - 2 years ago

Commercial Manufacturing of Eftilagimod Alpha at 2000L Scale Granted Authorization for Clinical Trial Use

Immutep to Participate in September Investor Conferences

Sep 5, 2023, 9:00 AM EDT - 2 years ago

Immutep to Participate in September Investor Conferences

DARKP00L
DARKP00L Sep. 8 at 12:17 PM
$IMMP 08:13 on Sep. 08 2025 Immutep Limited Announces That An Abstract From Its EFTISARC-NEO Phase 2 Trial Has Been Accepted For Oral Presentation At The CTOS 2025 Annual Meeting In November. The Study Is The First To Evaluate Eftilagimod Alpha In A Neoadjuvant Setting, Combined With Radiotherapy And Keytruda, For Patients With Soft Tissue Sarcoma #tradeideas
0 · Reply
DARKP00L
DARKP00L Sep. 8 at 12:17 PM
$IMMP 08:12 on Sep. 08 2025 Immutep To Present Phase II EFTISARC-NEO Trial Data On Efti + KEYTRUDA Combo In Soft Tissue Sarcoma At CTOS 2025 #tradeideas
0 · Reply
DARKP00L
DARKP00L Sep. 8 at 12:16 PM
$IMMP 08:07 on Sep. 08 2025 Immutep Limited Announces That An Abstract From Its EFTISARC-NEO Phase 2 Trial Has Been Accepted For Oral Presentation At The CTOS 2025 Annual Meeting In November. The Study Is The First To Evaluate Eftilagimod Alpha In A Neoadjuvant Setting, Combined With Radiotherapy And Keytruda, For Patients With Soft Tissue Sarcoma #tradeideas
0 · Reply
theinvestaar
theinvestaar Sep. 8 at 2:36 AM
$IMMP News out!!! yeah baby another oral presentation for November in soft tissue sarcoma. Things are heating up now.
0 · Reply
BigTimePennyStocks
BigTimePennyStocks Sep. 7 at 8:59 PM
Small-Caps with Catalysts this week: 👇👇 ( $GNPX, $AEMD, $NXL, $IMMP, $COCP, etc...) #NASDAQ #NYSE
0 · Reply
NOCKNOCK
NOCKNOCK Sep. 5 at 7:37 PM
$IMMP 👇one thing for certain, I'll be here to find out.
0 · Reply
bylocehi
bylocehi Sep. 5 at 6:37 PM
$IMMP The new investigator initiated breast cancer trial at George Washington seeks to determine pathological complete response (pCR) after neoadjuvant chemotherapy (NAC) and Efti treatment Their protocol seems different than other studies. Do these guy think the can cure cancer by priming APCs with eftilagimod first then use current therapies to provide APCs with cancer antigens to optimize cellular immune response? This could be the big breakthrough we need.
0 · Reply
hendo7179
hendo7179 Sep. 5 at 5:10 AM
$IMMP absolute trash, year after year talks of a buyout, and here we are close to the end of 2025 and looking down the barrel of another CR.
0 · Reply
theinvestaar
theinvestaar Sep. 5 at 4:16 AM
$IMMP Sooooon
0 · Reply
Jagr99
Jagr99 Sep. 5 at 12:33 AM
$IMMP trash
0 · Reply
Messerschmittbf109
Messerschmittbf109 Sep. 4 at 6:48 PM
$THAR another pump and dump stock $VYNE $JSPR $IMMP hard times
0 · Reply
rispi
rispi Sep. 4 at 6:27 AM
$IMMP month after month the CEO is bringing you into a new offer. careful buddy
1 · Reply
theinvestaar
theinvestaar Sep. 4 at 2:20 AM
$IMMP
0 · Reply
NOCKNOCK
NOCKNOCK Sep. 3 at 9:24 PM
$IMMP gonna kick the can another month huh, lol. The criminals are begging to be plunged into war. Aren't you...
0 · Reply
theinvestaar
theinvestaar Sep. 3 at 6:57 PM
$IMMP https://www.immutep.com/immutep-announces-abstracts-accepted-for-presentation-at-the-european-society-for-medical-oncology-congress-2025/ Oral in October.
1 · Reply
IFeelLike
IFeelLike Sep. 3 at 1:36 PM
$IMMP Seems to be oral. Also October ESMO is coming up. A Proffered Paper oral presentation will detail results from EFTISARC-NEO, a Phase II investigator-initiated trial in resectable soft tissue sarcoma, and data from the INSIGHT-003 Phase I investigator-initiated trial in first-line non-small cell lung cancer (1L NSCLC) has been accepted for poster presentation. Additionally, an abstract on the Company’s pivotal TACTI-004 Phase III in 1L NSCLC has been accepted for a Trials in Progress ePoster. 18th and 19th of October
1 · Reply
elmono
elmono Sep. 3 at 10:13 AM
$IMMP poster presentation instead of oral presentation….sounds like a nothing burger to me
1 · Reply
theinvestaar
theinvestaar Sep. 3 at 3:36 AM
$IMMP Let's go!!!!
1 · Reply
Pupssavethe
Pupssavethe Sep. 2 at 2:24 PM
$IMMP
0 · Reply
Nico07
Nico07 Sep. 2 at 8:17 AM
$IMMP 6 trading days!! Let’s go Immutep!
1 · Reply
lucgallo
lucgallo Sep. 1 at 9:10 AM
$IMMP Annual report 2025 published august 29, 2025. https://www.immutep.com/investors-media/asx-announcements/
1 · Reply
Nico07
Nico07 Aug. 30 at 12:06 PM
$IMMP
0 · Reply